NIKKEI 225
38,617.10 -329.83 (-0.85%) HANG SENG
19,195.60 -25.02 (-0.13%) CRUDE OIL
78.05 -0.61 (-0.78%) GOLD FUTURES
2,394.90 -31.00 (-1.28%) DOW
39,836.56 -36.43 (-0.09%) Bitcoin GBP
55,160.74 +326.77 (+0.60%)
Protara Therapeutics, Inc. (TARA)
| Previous close | 2.9300 |
| Open | 2.9200 |
| Bid | 2.9000 x 400 |
| Ask | 3.0100 x 100 |
| Day's range | 2.8300 - 2.9750 |
| 52-week range | 1.0400 - 5.2400 |
| Volume | |
| Avg. volume | 384,824 |
| Market cap | 60.563M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Tuesday, May 28, 2024 at 3:00 pm ET. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://i
- GlobeNewswire
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBCPreliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024Reached alignment with FDA on registrational path forward for IV Choline Chloride in patients dependent on parenteral nutritionCurrent cash resources, together with approximately $45.0 million in gross proceeds from April 2024 private placement, expected to fund operat
- GlobeNewswire
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement for the sale of an aggregate of 9,143,380 shares of its common stock (Shares) or, for certain purchasers, pre-funded warrants
